The Right Drug or Trial for Every Patient. This is the OmniSeq Mission.

OmniSeq® was founded with one purpose in mind: To inform physicians and their patients of the most actionable tumor-profiling information possible. We know that, when we accomplish this goal, we’re enabling patients to benefit from personalized treatment that will help them fight their illness at a molecular level.

At Omniseq®, we advance personalized medicine by focusing solely on the improvement of patient outcomes.

This is Who We Are.

Founded in 2015, OmniSeq® is a commercial, CAP accredited, CLIA and New York State CLEP licensed clinical laboratory in Buffalo, New York. We utilize next generation sequencing (NGS) technologies through New York State CLEP approved comprehensive molecular profiling, as well as offer a wide variety of pharmaceutical services to assist in drug development.

This is Our Legacy.

Roswell Park Comprehensive Cancer Center in Buffalo, New York is a pioneer clinical research facility for advanced treatment of all forms of adult and pediatric cancer, and a Member of the National Comprehensive Cancer Network. Roswell Park Comprehensive Cancer Center’s Founder, Dr. Roswell Park, sought to cure cancer and advocated a close connection between laboratory and clinical research to speed up discovery, and Roswell Park Comprehensive Cancer Center was the first institution to focus exclusively on cancer research.

After more than a century, Roswell Park Comprehensive Cancer Center continues to be at the forefront of groundbreaking cancer research. The institute’s history includes initiating the first experiments in chemotherapy in 1904; becoming America’s first Comprehensive Cancer Center; and providing the source, RP11 (RP stands for Roswell Park), for much of the BAC clone library used in the Human Genome Project.

OmniSeq® emerged from the Roswell Park Comprehensive Cancer Center’s Center of Personalized Medicine, and the breakthrough research, scientific expertise, and commitment to improving patient care define what OmniSeq® is today.

Dr. Carl Morrison, Founder of OmniSeq® and Executive Director of the Center for Personalized Medicine at Roswell Park Comprehensive Cancer Center, first envisioned the role of more advanced bioinformatics in clinical decision support while working at Roswell Park.

OmniSeq Laboratory Team

Roger D. Klein, MD, JD, FACP

Chief Medical Officer

Roger D. Klein, MD JD is a board-certified molecular pathologist who has served as medical director of molecular oncology and at several academic institutions, most recently Cleveland Clinic. In addition, he has served as a medical, strategic, and regulatory consultant in the biotechnology, clinical laboratory, diagnostics, and medical devices industries.

Shengle Zhang, MD

Laboratory Director

Dr. Zhang serves as OmniSeq’s Laboratory Director. Dr. Zhang, a board-certified molecular diagnostic and molecular genetic pathologist, has more than 30 years of proven experience in the molecular diagnostic oncology space, both as a practitioner and in the academic research space.

Sean Glenn, PhD

SVP, Laboratory Operations and Research Development
Assistant Laboratory Director

Dr. Glenn serves in a dual role within OmniSeq as SVP of Laboratory Operations and Research Development and Assistant Laboratory Director. Dr. Glenn has overall responsibility of laboratory operations including R&D and clinical services, and performs sign-out of NGS panel testing.

Jeffrey Conroy

Jeffrey Conroy

Chief Scientific Officer

Jeffrey Conroy serves as Chief Scientific Officer for OmniSeq. He oversees the scientific functions of OmniSeq, including Research and Development (R&D), Bioinformatics and Information Technology.  

OmniSeq Executive Team

Margot Schoenborn

Chief Executive Officer

Margot Schoenborn serves as Chief Executive Officer and a member of the Board of Directors.  She is responsible for leading corporate strategy and oversight of all commercial and corporate functions, while partnering with the Company’s leadership team to enable OmniSeq to realize the potential of its genomic testing and next-generation sequencing (NGS) assays in clinical and research settings. 

Paul DePietro, PhD

Executive Director, Knowledge Informatics

Paul DePietro leads the design and development of the OmniSeq Knowledgebase that serves targeted therapy, immunotherapy, and clinical trial information to OmniSeq clinical and research products.

Chris Drescher

SVP, Corporate Strategy and Business Development

As Senior Vice President of Corporate Strategy and Business Development, Chris is responsible for driving business strategy and technology commercialization across OmniSeq’s pharmaceutical services and clinical testing businesses. In this role, he is responsible for developing partnerships with pharmaceutical, biotech and research organizations to leverage OmniSeq’s multi-modal molecular testing platforms for biomarker discovery and clinical development.

Sarah Howath

Executive Director, Payer and Client Relations

Sarah Howarth leads the managed care, billing and customer service functions for OmniSeq and has over 15 years of healthcare experience leading billing and customer service teams.

Mary K. Nesline

SVP, Clinical Evidence Development

As SVP of Clinical Evidence Development, Mary Nesline establishes and executes measurement strategies and studies that support clinical utility for the OmniSeq product portfolio, supports product reimbursement and distribution strategies, and leverages OmniSeq testing assets for external pharmaceutical and academic business development.

Daria Shanchuk, CPA, MBA

VP, Finance

Daria Shanchuk leads the finance and budgeting functions for OmniSeq and has over 20 years of accounting and management experience.

William Stoll

Executive Director, Regulatory Affairs and Quality Assurance

Bill Stoll is responsible for establishing and maintaining FDA 21 CFR Part 820 and ISO 13485:2016 Quality Systems compliance and certification at OmniSeq.

OmniSeq Board of Directors

Paul Billings, MD, Ph.D, FACP, FACGMP

Chief Medical Officer, Natera
OmniSeq Chairman

Paul Billings, MD, Ph.D, FACP, FACGMP is a Board certified internist and clinical geneticist. Dr. Billings is the Chairman of Biological Dynamics, Inc., an innovative cancer testing company in San Diego, CA and is also the CMO of Natera.

Steven M. Anderson, PhD

Chief Scientific Officer-Covance, Sr VP, LabCorp

Dr. Anderson is a Senior Vice President at Laboratory Corporation of America (LabCorp), and the Chief Scientific Officer for the Covance Drug Development business of LabCorp. He has been with the LabCorp organization for 26 years and has held a variety of positions including Director of Operations for ViroMed Laboratories.

Marcia Eisenberg, PhD

Chief Scientific Officer and SVP, LabCorp

Marcia Eisenberg, PhD is Chief Scientific Officer and Senior Vice President at LabCorp Diagnostics. Dr. Eisenberg earned a BS in biology, a BA in psychology, and an MS in molecular biology from the State University of New York at Albany. She completed her PhD in molecular biology from the University of Kentucky.

Mark Gardner, MBA

Senior Vice President, Corza Health

Mark Gardner is the Senior Vice President of Business Development for Corza Health. Prior to this role Mark served as the Chief Executive Officer of OmniSeq. Mark has spent over twelve years in various executive roles at Thermo Fisher Scientific (previously Life Technologies).

Kelvin P. Lee, MD

Director, Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Kelvin Lee, M.D., a world-recognized medical oncologist and multiple myeloma researcher, is director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center. He began Feb. 1, 2021.

He is also associate dean of cancer research, H.H. Gregg Professor of Oncology, and professor of medicine and microbiology and immunology at IU School of Medicine. In addition, he is a physician at IU Health.

Margot Schoenborn, Esq.

Chief Executive Officer, OmniSeq

Margot Schoenborn is the Chief Executive Officer with experience in corporate development, transactions, capital market activities, corporate finance, and leadership of multi-functional teams over a nearly 20 year career in healthcare, law enforcement, and commercial litigation.

R. Buford Sears

R. Buford Sears has held various management positions for banks, most recently as KeyBank’s Regional President for Western New York, in charge of commercial lending. He is a member of the board of directors of Roswell Park Comprehensive Cancer Center, chairs the Roswell Park’s Finance Committee, and has vast expertise in commercial real estate and equipment financing, healthcare and government banking activities. Mr. Sears earned a BA in International Studies from the University of North Carolina at Chapel Hill and an MA in International Economics from Johns Hopkins University. Mr. Sears has served on OmniSeq’s Board of Directors since 2015.

Dennis Szefel

Strategic Advisor, Delaware North

Dennis Szefel was with Delaware North for more than 47 years, he served as chairman of Delaware North International, the company’s global business unit representing its businesses in Australia, New Zealand and Europe. He was named to the newly created position in July 2010 and given responsibility for developing a business, operational and global growth strategy.